1.Large sample clinical analysis of patients with children acute leukemia in single center.
Hui-Min ZENG ; Ye GUO ; Xiao-Li YI ; Jian-Feng ZHOU ; Wen-Bin AN ; Xiao-Fan ZHU
Journal of Experimental Hematology 2011;19(3):692-695
In order to investigate the epidemiology of childhood acute leukemia (CAL), such as onset age and time, risk factor, subtypes distribution and genetics, 1236 CAL patients admitted in blood disease hospital of Chinese Academy of Medical Sciences for treatment from April 2004 to April 2010 were analyzed retrospectively. The results showed that the sex ratio of ALL and AML patients were 1.80:1 and 1.73:1 respectively; the average peak age of incidence lasted from 2 to 6 years with the median age of 6 years, while the ALL peak age of incidence lasted from 2 to 5 years but AML showed no significant peak age of incidence. Winter, especially January was the peak time for both onset and birth. Among all the 631 ALL patients who had already been immunophenotyped, B-ALL patients accounted for 83%, T-ALL patients accounted for 9%. Among 361 AML patients, sub-leukemia phenotype from M(0) to M(7) accounted for 0.3%, 2.2%, 29.8%, 20.9%, 8.1%, 25.2%, 4.1% and 4.6% respectively. Among 631 pediatric ALL patients who had been examined by using molecular biology technique, the positive rate of TEL/AML1, BCR/ABL, MLL and E2A/PBX1 were 23%, 7.4%, 4.1%, 2.1% respectively. Among 361 pediatric AML patients who had been examined by using molecular biology technique, 19% of the patients showed positive AML1/ETO fusion gene, 18% of the patients showed positive PML/RARα fusion gene, while 4.2% of patients showed positive CBFβ/MYH11. It is concluded that the onset of pediatric acute leukemia is influenced by age, season, environment and different genetic background.
Age of Onset
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Leukemia
;
epidemiology
;
Leukemia, Myeloid, Acute
;
epidemiology
;
Male
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
epidemiology
;
Retrospective Studies
2.Biologic features of 688 cases of childhood acute leukemia-a single centre retrospective study.
Ye GUO ; Yu-Mei CHEN ; Yao ZOU ; Xiao-Juan CHEN ; Li ZHANG ; Shu-Chun WANG ; Xiao-Fan ZHU
Chinese Journal of Contemporary Pediatrics 2009;11(10):793-796
OBJECTIVETo investigate the biologic features of childhood acute leukemia in the northern region of China through a small cohort study in a single center.
METHODSThe medical records of 688 children with acute leukemia (age< or =15 years) who were initially diagnosed at Blood Disease Hospital of Chinese Academy of Medical Sciences from October 2003 to June 2006 were retrospectively studied.
RESULTSFour hundred children were diagnosed as acute lymphoblastic leukemia (ALL), with a peak incidence at ages of 1-4 years. Two hundred and eighteen children were classified into B-cell ALL, and 34 into T-cell ALL. In the 154 patients with cytogenetic data, high hyperdiploidy was presented in 13.0% of patients, low hyperdiploidy in 3.9%, pseudodiploidy in 5.2%, and hypodiploidy in 5.8%. E2A-PBX1 fusion gene was expressed in 3.9% of children with B-cell ALL. Two hundred and twenty-two children were diagnosed as acute myeloid leukemia (AML), with a peak incidence at ages of 10-15 years. AML-M2 was the most common subtype. Acute hybrid leukemia (AHL) was confirmed in 24 children (4.2%), with a median age of 9 years. Seventy-four percent of the children with (AHL) had mainly CD13 and CD33 expression in myeloid antigen integral.
CONCLUSIONSThere are differences in the biologic features of childhood acute leukemia between the northern region of China and other regions and races, which suggests that there might be differences in the pathogenesis of childhood acute leukemia in different environmental exposures.
Adolescent ; Child ; Child, Preschool ; China ; epidemiology ; Female ; Humans ; Infant ; Infant, Newborn ; Leukemia, Myeloid, Acute ; epidemiology ; genetics ; immunology ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; epidemiology ; genetics ; immunology ; Retrospective Studies
3.Association between meat, fish, and fatty acid intake and incidence of acute myeloid leukemia and myelodysplastic syndrome: the Japan Public Health Center-based Prospective Study.
Yoshimitsu SHIMOMURA ; Tomotaka SOBUE ; Ling ZHA ; Tetsuhisa KITAMURA ; Motoki IWASAKI ; Manami INOUE ; Taiki YAMAJI ; Shoichiro TSUGANE ; Norie SAWADA
Environmental Health and Preventive Medicine 2023;28():19-19
BACKGROUND:
The association between meat, fish, or fatty acid intake and acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has been investigated in a few studies, and the results were inconsistent. In addition, most studies are mainly based on the United States and European countries, in which the dietary patterns differ from that in Asia. Therefore, the risk of AML/MDS from meat, fish, or fatty acid intake in Asia requires further exploration. The aim of this study was to investigate the association between AML/MDS incidence and meat, fish, or fatty acid intake using the Japan Public Health Center-based prospective study.
METHODS:
The present study included 93,366 participants who were eligible for analysis and followed up from the 5-year survey date until December 2012. We estimated the impact of their intake on AML/MDS incidence using a Cox proportional hazards model.
RESULTS:
The study participants were followed up for 1,345,002 person-years. During the follow-up period, we identified 67 AML and 49 MDS cases. An increased intake of processed red meat was significantly associated with the incidence of AML/MDS, with a hazard ratio of 1.63 (95% confidence interval, 1.03-2.57) for the highest versus lowest tertile and a Ptrend of 0.04. Meanwhile, the intake of other foods and fatty acids was not associated with AML/MDS.
CONCLUSION
In this Japanese population, processed red meat was associated with an increased incidence of AML/MDS.
Animals
;
Japan/epidemiology*
;
Prospective Studies
;
Incidence
;
Public Health
;
Meat/adverse effects*
;
Fatty Acids/adverse effects*
;
Leukemia, Myeloid, Acute
;
Myelodysplastic Syndromes/epidemiology*
4.Incidence estimation of leukemia among Koreans.
Yoon Ok AHN ; Hong Hoe KOO ; Byung Joo PARK ; Keun Young YOO ; Moo Song LEE
Journal of Korean Medical Science 1991;6(4):299-307
This study was undertaken in order to estimate the incidence of leukemia among Koreans. Medical records were studied of patients with diagnoses of either ICD-9 038 (septicemia), or 204-208 (leukemias), or 284 (aplastic anemia), or 289 (other diseases of the blood and blood-forming organs) in the claims sent in by medical care institutions throughout the country to the Korea Medical Insurance Corporation (KMIC) during the period from January 1, 1986 to December 31, 1987. These records were abstracted in order to identify and confirm new cases of leukemia among the beneficiaries of KMIC, which covers about 10% of the whole Korean population. Using these data from the KMIC, the incidence rates of leukemia among Koreans were estimated as of July 1st, 1986 to June 30, 1987. The crude incidence rate of all types of leukemia among Koreans is estimated to be 3.45 (95% CI; 0.77-9.55) and 2.29 (95% CI; 0.28-7.81) per 100,000 in males and females, respectively. The cumulative rate for the age span 0-64 is 0.25% in males and 0.18% in females, and for the age span 0-74, 0.35% in males and 0.23% in females. The adjusted rates for the standard world population are 3.90 and 2.48 per 100,000 in males and females, respectively. The relative frequencies by type are 51.5% for AML, 21.6% for ALL, 20.2% for CML, and only 1.5% for CLL. The incidence patterns of various types of leukemia, of which this is the first report in Korea, are analyzed and presented.(ABSTRACT TRUNCATED AT 250 WORDS)
Adolescent
;
Adult
;
Age Factors
;
Aged
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Incidence
;
Infant
;
Korea/epidemiology
;
Leukemia/*epidemiology
;
Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology
;
Leukemia, Myeloid, Acute/epidemiology
;
Male
;
Middle Aged
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology
;
Sex Factors
5.Clinical observation of patients with hematologic malignancies treated with hematopoietic stem cell transplantation.
Donghua ZHANG ; Lu ZHANG ; Yi XIAO ; Wei HUANG ; Dengju LI ; Dan RAN ; Liang HUANG ; Jianfeng ZHOU ; Mei HUANG ; Hanying SUN ; Wenli LIU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2004;24(4):345-349
To evaluate the therapeutic effect of hematopoietic stem cell transplantation (HSCT), we performed HSCT in 30 patients with hematologic maligancies. Of the 30 patients, 10 underwent autologous peripheral blood stem cell transplantation (auto-PBSCT), 13 underwent myeloablative allogeneic HSCT while 7 underwent nonmyeloablative allogeneic HSCT, which were designated as autologous group, myeloablative group and nonmyeloablative group, respectively. All patients except the one who underwent cord blood transplantation, were successfully engrafted. Median time for the granulocytes > or = 0.5 x 10(9)/L and platelets > or = 20 x 10(9)/L were 12 days and 13 days respectively in autologous group, 16 days and 19 days in myeloablative group, 15 days and 12 days in nonmyeloablative group. In myeloablative group, acute graft-versus-host diseases (aGVHD) was observed in 3 patients, all of which were I-II grade. Oral mucous cGVHD was observed in 1 patient. In nonmyeloablative group, 1 patient developed intestinal aGVHD grade IV and cutaneous cGVHD was induced by donor lymphocyte infusions (DLI) in 3 patients. 1 patient had hematological relapse in autologous group. 1 patient had cytogenetic relapse in myeloablative group. In nonmyeloablative group 3 patients had cytogenetic relapse and were cured by DLI, 1 patient had hematological relapse. 4 of the 30 patients died of infection (2 patients), grade IV aGVHD (1) and relapse (1) respectively. 26 patients are still alive. 3 years overall survival (OS) and 3 years disease free survival (DFS) were 100% and 64.81% respectively in autologous group, 78.75% and 63% respectively in myeloablative group while both 66.67% in nonmyeloablative group. In conclusion, autologous group had less transplant-related complications and mortality. Active prophylaxis of relapse could significantly promote DFS. The transplant-related mortality limited DFS in myeloablative group. More relapses occurred in nonmyeloablative group, but could be cured by DLI.
Adolescent
;
Adult
;
China
;
epidemiology
;
Female
;
Follow-Up Studies
;
Graft vs Host Disease
;
epidemiology
;
Hematopoietic Stem Cell Transplantation
;
adverse effects
;
Humans
;
Leukemia
;
surgery
;
Leukemia, Myeloid, Acute
;
surgery
;
Leukemia, Myelomonocytic, Chronic
;
surgery
;
Lymphoma
;
surgery
;
Male
;
Middle Aged
6.Allogeneic peripheral blood hematopoietic stem cell transplantation for patients with hematologic malignancies.
Linghui, XIA ; Jun, FANG ; Yong, YOU ; Tao, GUO ; Fang, LIU ; Chun, ZHANG ; Huijuan, JIANG ; Ping, ZOU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2006;26(1):47-9
To investigate the therapeutic effects and associated complications of allogeneic peripheral blood stem cell transplantation (allo-PBSCT). 40 patients with various malignant hematopoietic diseases received allo-PBSCT. The preparative regimens were based on BUCY2 or modified BUCY2. The acute graft-versus host disease (aGVHD) was prevented by cyclosporin A and short-term MTX regimen in all patients. Two patients from donors with one fully mismatched HLA on DRB1 locus and 4 from unrelated donor also administered Zenapox (CD25 MAb) at dosage of 1 mg/kg every day on the day before transplantation and day 4 after transplantation. These 6 patients were also treated with mycophenolate mofetil (MMF). Transfusion of the donor cells: The median of the transfused nucleated cells was 5.38 x 10(8)/kg and that of the CD34+ cells was 7.8 x 10(6)/kg respectively. All the patients gained hematopoietic reconstruction except one who died of infection before engraftment. Seven patients got II degrees-IV degrees aGVHI) and the incidence was 17.5%. Fourteen patients got cGVHD and the incidence was 53.8% in the patients who survived over 6 months. Twenty-eight patients had fever or other characteristics of infection. The median follow-up time was 13.8 months. The incidence of transplantation related mortality (TRM) was 17.5% and 2 patients relapsed (5.0%). It was concluded that allo-PBSCT can reconstruct hematopoiesis quickly and is a favorable therapeutic method for leukemia.
China/epidemiology
;
Cyclosporine/*therapeutic use
;
Follow-Up Studies
;
Graft vs Host Disease/*prevention & control
;
Leukemia/*therapy
;
Leukemia, Lymphoid/therapy
;
Leukemia, Myeloid, Acute/therapy
;
*Peripheral Blood Stem Cell Transplantation/adverse effects
;
Sepsis/epidemiology
;
Sepsis/etiology
7.Skin manifestation of Stenotrophomonas maltophilia infection--a case report and review article.
Wan Yee TEO ; Mei Yoke CHAN ; Ching Mei LAM ; Chia Yin CHONG
Annals of the Academy of Medicine, Singapore 2006;35(12):897-900
INTRODUCTIONStenotrophomonas maltophilia is an aerobic gram-negative bacillus that is a frequent coloniser of fluids used in the hospital setting. It causes infection in immunosuppressed hosts, especially those who are neutropaenic, on chemotherapy and broad spectrum antibiotics. Skin and soft tissue manifestations of Stenotrophomonas maltophilia infection are becoming an increasingly recognised entity; the clinical spectrum ranges from mucocutaneous, skin to soft tissue infections.
MATERIALS AND METHODSWe present a case of an 8-year-old girl with acute myeloid leukaemia who developed metastatic skin lesions secondary to Stenotrophomonas maltophilia bacteraemia. The authors reviewed a total of 24 reported cases of mucocutaneous, skin and soft tissue infections by Stenotrophomonas maltophilia. The presentations include metastatic cellulitis, primary cellulitis and infected mucocutaneous ulcers.
RESULTSThis is the first locally reported case of metastatic nodular skin lesions caused by Stenotrophomonas maltophilia bacteraemia. This is also the first reported paediatric case of embolic skin lesions caused by Stenotrophomonas maltophilia. Of the 6 cases of Stenotrophomonas maltophilia bacteraemia seen in the paediatric oncology patients from year 2000 to 2004 at our hospital, only 1 case developed metastatic skin lesions.
CONCLUSIONStenotrophomonas maltophilia skin infection should be included into the list of differential diagnoses for metastatic skin lesions in neutropaenic patients, especially with an underlying haematologic malignancy who has received recent chemotherapy and broad spectrum antibiotics. Haematologic malignancy, transplantation, neutropaenic, immunosuppressive therapy and a high severity of illness score were important prognostic factors.
Acute Disease ; Anti-Infective Agents ; therapeutic use ; Bacteremia ; epidemiology ; microbiology ; Cellulitis ; epidemiology ; microbiology ; Child ; Comorbidity ; Female ; Gram-Negative Bacterial Infections ; complications ; Humans ; Leukemia, Myeloid ; epidemiology ; Neutropenia ; epidemiology ; Prognosis ; Skin Diseases, Bacterial ; epidemiology ; Stenotrophomonas maltophilia ; Trimethoprim, Sulfamethoxazole Drug Combination ; therapeutic use
8.Clinical Characteristics and Risk Factors of Invasive Fungal Infections in Acute Leukemia Patients in Tropical Regions.
Wen-Shuai ZHENG ; Li-Xun GUAN ; Shen-Yu WANG ; Ya-Lei HU ; Bo PENG ; Jian BO ; Quan-Shun WANG ; Xiao-Ning GAO
Journal of Experimental Hematology 2022;30(1):99-106
OBJECTIVE:
To analyze the clinical characteristics and risk factors of invasive fungal infection (IFI) occurenced in patients with acute leukemia (AL) during treatment in tropical regions.
METHODS:
The clinical data of 68 AL patients admitted to the Hainan Hospital of PLA General Hospital from April 2012 to April 2019 was retrospectively analyzed. Logistic regression analysis was used to analyze the factors affecting the occurrence of IFI in AL patients.
RESULTS:
Among the 68 patients, 44 were acute myeloid leukemia, 24 were acute lymphoblastic leukemia, 39 were male, 29 were female and the median age was 41(13-75) years old. The 68 patients received 242 times of chemotherapy or hematopoietic stem cell transplantation(HSCT), including 73 times of initial chemotherapy or inducting chemotherapy after recurrence, 14 times of HSCT, 155 times of consolidating chemotherapy. Patients received 152 times of anti-fungal prophylaxis, including 77 times of primary anti-fungal prophylaxis and 75 times of secondary anti-fungal prophylaxis. Finally, the incidence of IFI was 31 times, including 24 times of probable diagnosis, 7 times of proven diagnosis, and the total incidence of IFI was 12.8%(31/242), the incidence of IFI in inducting chemotherapy was 24.66%(18/73), the incidence of IFI in HSCT patients was 28.57% (4/14), the incidence of IFI in consolidating chemotherapy was 5.80% (9/155). Multivariate analysis showed that inducting chemotherapy or HSCT, the time of agranulocytosis ≥7 days, risk stratification of high risk were the independent risk factors for IFI in AL patients during treatment in tropical regions.
CONCLUSION
The incidence of IFI in patients with AL in the tropics regions is significantly higher than that in other regions at homeland and abroad. Anti-fungal prophylaxis should be given to the patients with AL who have the high risk factors of inducting chemotherapy or HSCT, time of agranulocytosis ≥7 days and risk stratification of high risk.
Adult
;
Aged
;
Antifungal Agents/therapeutic use*
;
Female
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Invasive Fungal Infections/epidemiology*
;
Leukemia, Myeloid, Acute/drug therapy*
;
Male
;
Middle Aged
;
Retrospective Studies
;
Risk Factors
9.Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation.
Yan CHEN ; Yajing XU ; Yan ZHU ; Gan FU ; Yi LIU ; Jie PENG ; Bin FU ; Qun HE ; Dengshu WU ; Xiaolin LI ; Xielan ZHAO ; Fangping CHEN
Journal of Central South University(Medical Sciences) 2011;36(9):859-864
OBJECTIVE:
To study the efficacy of allogeneic hemotopoietic stem cell transplantation (allo-HSCT) for hematological malignancy.
METHODS:
A total of 104 patients with hematological malignancy, who underwent allo-HSCT in Xiangya Hospital from December 1999 to January 2010, were retrospectively analyzed. Of the patients, the transplantation related mortality (TRM), relapse rate (RR), 5-year overall survival (OS) and disease free survival (DFS) were estimated by Kaplan-Meier analysis. The unfavorable prognostic factors were also statistically examined.
RESULTS:
Hematopoietic reconstitution was achieved in 101 patients. At the last data of follow-up, the incidences of severe acute graft versus host disease (aGVHD) and extensive chronic GVHD were 15.38% and 25.53%, and the TRM and RR were 15.66% and 21.76%, respectively. The estimated 5-year OS and DFS for all patients were (73.49±4.59)% and (63.10±5.32)%, respectively. Those for acute myeloid leukemia (AML) patients were (63.00±9.51)% and (49.30±9.96)%, and those for chronic myeloid leukemia (CML) patients were (83.87±5.06)% and (74.55±6.79)%, respectively. The survival analysis suggested the poor prognostic factors for allo-HSCT recipients including female sex, severe aGVHD and refractory hematological malignancy. Further multivariate analyses revealed that severe aGVHD and refractory hematological malignancy were the independent risk factors of poor prognosis for the recipients (P<0.05). The 5-year DFS of severe aGVHD and refractory hematological malignancy patients was (48.22±12.69)% and (42.09±12.31)%, respectively. The TRM of severe aGVHD, HLA-mismatched graft and unrelated donor transplant was significantly higher than that of the corresponding control groups (57.14% vs. 4.81%, 33.33% vs. 10.41%, 26.09% vs. 9.28%; P<0.05). The RR of refractory hematological malignancy was significantly higher than that of the control group (41.09% vs. 15.63%, P<0.05).
CONCLUSION
The treatment of allo-HSCT can improve the disease free survival of patients with hematological malignany and is an important therapeutic method for hematological malignancy. Severe aGVHD and refractory hematological malignancy are the independent risk factors of poor prognosis for the allo-HSCT recipients with hematological malignancy.
Adolescent
;
Adult
;
Child
;
China
;
epidemiology
;
Female
;
Graft vs Host Disease
;
epidemiology
;
Hematologic Neoplasms
;
therapy
;
Hematopoietic Stem Cell Transplantation
;
methods
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
therapy
;
Leukemia, Myeloid, Acute
;
therapy
;
Male
;
Middle Aged
;
Retrospective Studies
;
Transplantation, Homologous
;
Young Adult
10.Surgical Roles for Spinal Involvement of Hematological Malignancies.
Sang Il KIM ; Young Hoon KIM ; Kee Yong HA ; Jae Won LEE ; Jin Woo LEE
Journal of Korean Neurosurgical Society 2017;60(5):534-539
OBJECTIVE: Patients with hematological malignancies frequently encounter spine-related symptoms, which are caused by disease itself or process of treatment. However, there is still lack of knowledge on their epidemiology and clinical courses. The purpose of this article is to review clinical presentations and surgical results for spinal involvement of hematologic malignancies. METHODS: From January 2011 to September 2014, 195 patients (98 males and 97 females) suffering from hematological malignancies combined with spinal problems were retrospectively analyzed for clinical and radiological characteristics and their clinical results. RESULTS: The most common diagnosis of hematological malignancy was multiple myeloma (96 patients, 49.7%), followed by chronic myeloid leukemia (30, 15.2%), acute myeloid leukemia (22, 11.2%), and lymphoma (15, 7.56%). The major presenting symptoms were mechanical axial pain (132, 67.7%) resulting from pathologic fractures, and followed by radiating pain (49, 25.1%). Progressive neurologic deficits were noted in 15 patients (7.7%), which revealed as cord compression by epidural mass or compressive myelopathy combined with pathologic fractures. Reconstructive surgery for neurologic compromise was done in 16 patients. Even though surgical intervention was useful for early paralysis (Frankel grade D or E), neurologic recovery was not satisfactory for the progressed paralysis (Frankel grade A or B). CONCLUSION: Hematological malignancies may cause various spinal problems related to disease progression or consequences of treatments. Conservative and palliative treatments are mainstay for these lesions. However, timely surgical interventions should be considered for the cases of pathologic fractures with progressive neurologic compromise.
Diagnosis
;
Disease Progression
;
Epidemiology
;
Fractures, Spontaneous
;
Hematologic Neoplasms*
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
Leukemia, Myeloid, Acute
;
Lymphoma
;
Male
;
Multiple Myeloma
;
Neurologic Manifestations
;
Palliative Care
;
Paralysis
;
Retrospective Studies
;
Spinal Cord Compression
;
Spinal Cord Injuries
;
Spine